In years gone by, it was not too hard to write up a summary of Gevo, Solazyme and Amyris — all aimed at fuels, all in the development stage, all used synthetic biology in closed fermenters, all had big backers ranging from brand-name equity partners to big-time strategics, all went public in the same 2010-11 IPO window.